Ivermectin and COVID-19: Keeping Rigor in Times of Urgency
Resumen: Ivermectin is a widely used drug for the treatment and control of severalneglectedtropical diseases.1 Thedrughas anexcellent safety profile, with more than 2.5 billion doses distributed in the last 30 years, and its potential to reducemalaria transmission by killingmosquitoes is under evaluation in several trials around the world.2 Ivermectin inhibits the in vitro replicationof somepositive, single-stranded RNA viruses, namely, dengue virus (DNV),3–5 Zika virus,4,6 yellow fever virus,7,8 and others.4,7,9 Caly et al.10 recently reported that ivermectin is a potent inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro.Given the coronavirus disease- 19 (COVID-19) pandemic, this has understandably resonated widely in the global press.11
Caly et al.10 report a 5,000-fold reduction inSARS-CoV-2RNA levels, compared with those in controls, after infected Vero/ hSLAM cells were incubated for 48 hours with 5 µM ivermectin. The ivermectin IC50 for the viruswas calculated at approximately 2.5 µM. These concentrations are the equivalent of 4,370 and 2,190 ng/mL, respectively, notably 50- to 100-fold the peak concentration (Cmax) achieved in plasma after the single dose of 200 µg/kg (14mg in a 70-kg adult) commonly used for the control of onchocerchiasis.12 Pharmacokinetic studies in healthy volunteers have suggested that single doses up to 120 mg of ivermectin can be safe and well tolerated.13 However, even with this dose, which is 10-fold greater than those approved by the US...

Idioma: Inglés
DOI: 10.4269/ajtmh.20-0271
Año: 2020
Publicado en: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE 102, 6 (2020), 1156-1157
ISSN: 0002-9637

Factor impacto SCIMAGO:

Tipo y forma: (Versión definitiva)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.

Exportado de SIDERAL (2020-11-19-11:46:13)

Este artículo se encuentra en las siguientes colecciones:

 Registro creado el 2020-11-19, última modificación el 2020-11-19

Versión publicada:
Valore este documento:

Rate this document:
(Sin ninguna reseña)